During the course of the disease, APS occurred in 47 of 274 participants (17.2%) with AQP4 antibodies, while only 2 of 107 participants (1.9%) with MOG antibodies experienced APS (p < 0.001). The gene discussed is AQP4; the disease is autoimmune polyendocrinopathy.